Comparing of Gabapentin and Cinnarizine Effect on Tinnitus

Comparing of Gabapentin and Cinnarizine Effect on Tinnitus in Patients with Sensorineural Hearing Loss

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221002056073N1

Enrollment

114

Registered

2022-10-09

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus. Tinnitus

Interventions

Intervention 1: Intervention group: Cap Gabapentin 100mg/d 1st week, 300mg/d 2nd week (100mg q8h), 900mg/d 3th and 4th weeks (300mg q8h), 300mg/d 5th week (100mg q8h), 100mg/d 6th week- oral administr

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The patient has continuous tinnitus without pulsation for at least one year. Having sensorineural hearing loss Based on the Tinnitus Handicap Inventory (THI), the patient must have scored 38 or higher.

Exclusion criteria

Exclusion criteria: Having active Meniere's Disease Having Kidney Dysfunction Being pregnant or breastfeeding Having any of the following: Glaucoma, Urinary Retention, Prostate Hypertrophy, Epilepsy and Liver Disease Having a health condition that prohibits the use of Gabapentin for the patient or other Contraindications

Design outcomes

Primary

Measure	Time frame
Severity of tinnitus. Timepoint: At the beginning of the study (before the start of the intervention) and 6 weeks after starting the medication. Method of measurement: Tinnitus Handicap Inventory Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Samarei

Oroumia University of Medical Sciences

samarai.r@umsu.ac.ir+98 44 3345 9538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026